Medpace Holdings, Inc. (MEDP) All Metrics
MEDP Valuation Metrics
MEDP Stock Price Metrics
MEDP Dividend Metrics
MEDP Growth Rate Metrics
MEDP Discounted Cash Flow Metrics
| Fair Value Price | $433.81 |
| Margin of Safety | (5.09%) |
MEDP Revenue Metrics
MEDP PE Ratio Metrics
| PE Ratio | 28.71 |
| PE Ratio Avg TTM | 33.93 |
| PE Ratio Avg 3Y | 33.24 |
| Current VS TTM Avg | -15.38% |
| Current VS 3Y Avg | -13.62% |
| Current VS 5Y Avg | -13.33% |
MEDP PS Ratio Metrics
| PS Ratio | 4.94 |
| PS Ratio Avg TTM | 6.09 |
| PS Ratio Avg 3Y | 5.64 |
| Current VS TTM Avg | -18.82% |
| Current VS 3Y Avg | -12.38% |
| Current VS 5Y Avg | -9.46% |
MEDP PB Ratio Metrics
| PB Ratio | 22.13 |
| PB Ratio Avg TTM | 50.19 |
| PB Ratio Avg 3Y | 18.60 |
| Current VS TTM Avg | -55.91% |
| Current VS 3Y Avg | +18.95% |
| Current VS 5Y Avg | +39.43% |
MEDP Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 17.94 |
| PFCF Ratio Avg TTM | 21.95 |
| PFCF Ratio Avg 3Y | 22.58 |
| Current VS TTM Avg | -18.27% |
| Current VS 3Y Avg | -20.54% |
| Current VS 5Y Avg | -21.32% |
MEDP Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.55 |
| Debt/Equity Ratio Avg TTM | 0.36 |
| Debt/Equity Ratio Avg 3Y | 0.37 |
| Current VS TTM Avg | +50.68% |
| Current VS 3Y Avg | +49.66% |
| Current VS 5Y Avg | +88.57% |
MEDP PEG Ratio Metrics
| PEG Ratio | 1.82 |
| PEG Ratio Avg TTM | 1.22 |
| PEG Ratio Avg 3Y | 1.14 |
| Current VS TTM Avg | +49.79% |
| Current VS 3Y Avg | +60.00% |
| Current VS 5Y Avg | +54.89% |
MEDP FCF Yield
| FCF Yield | 5.57% |
| FCF Yield Avg TTM | 4.68% |
| FCF Yield Avg 3Y | 4.57% |
| Current VS TTM Avg | +18.90% |
| Current VS 3Y Avg | +21.90% |
| Current VS 5Y Avg | +23.42% |
MEDP Earnings Yield
| Earnings Yield | 3.48% |
| Earnings Yield Avg TTM | 3.05% |
| Earnings Yield Avg 3Y | 3.12% |
| Current VS TTM Avg | +14.19% |
| Current VS 3Y Avg | +11.58% |
| Current VS 5Y Avg | +11.13% |
MEDP EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 22.58 |
| Ev/Ebit Ratio Avg TTM | 28.21 |
| Ev/Ebit Ratio Avg 3Y | 28.08 |
| Current VS TTM Avg | -19.96% |
| Current VS 3Y Avg | -19.58% |
| Current VS 5Y Avg | -19.57% |
MEDP EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 21.18 |
| Ev/Ebitda Ratio Avg TTM | 26.03 |
| Ev/Ebitda Ratio Avg 3Y | 25.80 |
| Current VS TTM Avg | -18.64% |
| Current VS 3Y Avg | -17.90% |
| Current VS 5Y Avg | -17.31% |
MEDP EV/Assets Ratio Metrics
| Ev/Assets Ratio | 5.97 |
| Ev/Assets Ratio Avg TTM | 8.01 |
| Ev/Assets Ratio Avg 3Y | 6.58 |
| Current VS TTM Avg | -25.47% |
| Current VS 3Y Avg | -9.29% |
| Current VS 5Y Avg | +11.91% |
MEDP EV/Sales Ratio Metrics
| Ev/Sales Ratio | 4.74 |
| Ev/Sales Ratio Avg TTM | 6.02 |
| Ev/Sales Ratio Avg 3Y | 5.55 |
| Current VS TTM Avg | -21.22% |
| Current VS 3Y Avg | -14.59% |
| Current VS 5Y Avg | -12.13% |
MEDP Current Ratio Metrics
| Current Ratio | 0.74 |
| Current Ratio Avg TTM | 0.83 |
| Current Ratio Avg 3Y | 0.68 |
| Current VS TTM Avg | -11.38% |
| Current VS 3Y Avg | +8.42% |
| Current VS 5Y Avg | -12.08% |
MEDP Quick Ratio Metrics
| Quick Ratio | 0.74 |
| Quick Ratio Avg TTM | 0.83 |
| Quick Ratio Avg 3Y | 0.68 |
| Current VS TTM Avg | -11.38% |
| Current VS 3Y Avg | +8.42% |
| Current VS 5Y Avg | -12.08% |
MEDP ROIC Metrics
| ROIC | 67.94% |
| ROIC Avg 3Y | 46.08% |
| ROIC Avg 5Y | 35.95% |
| Current VS 3Y Avg | +47.44% |
| Current VS 5Y Avg | +88.98% |
| Current VS 10Y Avg | +196.98% |
MEDP Return on Assets Metrics
| ROA | 22.84 |
| ROA Avg TTM | 21.05 |
| ROA Avg 3Y | 19.32 |
| Current VS TTM Avg | +8.53% |
| Current VS 3Y Avg | +18.19% |
| Current VS 5Y Avg | +38.83% |
MEDP Return on Equity Metrics
| ROE | 98.27 |
| ROE Avg TTM | 73.63 |
| ROE Avg 3Y | 65.34 |
| Current VS TTM Avg | +33.47% |
| Current VS 3Y Avg | +50.40% |
| Current VS 5Y Avg | +97.55% |
MEDP Net Profit Margin Metrics
| Net Profit Margin | 17.83% |
| Net Profit Margin Avg TTM | 18.50% |
| Net Profit Margin Avg 3Y | 17.20% |
| Current VS TTM Avg | -3.62% |
| Current VS 3Y Avg | +3.65% |
| Current VS 5Y Avg | +6.52% |
Last Updated: Wednesday, June 17, 2026
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle